Search Results
Zanubrutinib in patients with CLL intolerant to ibrutinib and acalabrutinib
Safety and efficacy of zanubrutinib in patients who are intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib for ibrutinib/acalabrutinib intolerant R/R B-cell malignancies
Zanubrutinib in acalabrutinib-intolerant patients with various B-cell malignancies
Efficacy of zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Using Acalabrutinib in CLL Patients With Ibrutinib Intolerance
Updates on the use of zanubrutinib in WM patients intolerant to ibrutinib or acalabrutinib
Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL
Acalabrutinib And Zanubrutinib in CLL
Zanubrutinib improves PFS compared to ibrutinib for R/R CLL and small lymphocytic lymphoma
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
Zanubrutinib for BTK Inhibitor Intolerant Patients with CLL - Dr. Jeff Sharman ASH 2021
